In recent years, cell therapies have developed alongside chemotherapy and immunotherapy to become a new pillar in the treatment of patients with blood and lymph gland cancer. In solid tumors, such as ...

An autologous point-of-care cell therapy for adults with ischemic HF with reduced ejection fraction was safe and may be ...

“Our CB-SCs can target different compartments of the immune system, educating and correcting their dysfunctions at a fundamental level,” says Dr. Zhao. “This therapy has the potential to revolutionize ...

Treatment with regulatory T-cells, known as Tregs, was well tolerated and seemed to reduce disease activity in a small ...

During a live event, Jack Khouri, MD, discussed options for patients with multiple myeloma after relapse and choices to ...

Zimislecel is an allogeneic stem cell-derived islet cell therapy that could eliminate the need for insulin in those who have type 1 diabetes. Regulatory submissions are expected in 2026, and if ...

The first patient with relapsed or refractory CD5-positive T-cell lymphoma has been dosed with the CAR-T cell therapy MB-105.

USC researchers have developed an innovative type of cancer-fighting immune cell, the EchoBack CAR T-cell, that uses focused ...